This briefing serves as a one-stop-shop background tool on the evolving landscape of GLP-1s and weight management drugs, including insights on medical and surgical weight loss models, success factors, and common barriers within the hotly developing space.
Key Takeaways
Jury is still out on whether GLP-1s will reduce demand for bariatric surgery with estimates saying the drugs could reduce national health spending by ~$300B annually.
Compounded GLP-1s add complexity to the weight loss medication market as regulatory and legal challenges with compounding formularies are just beginning.
Anticipate a GLP-1 'price war' as manufacturers shore up facilities, pharma giants ramp up development of new drugs, compounding continues, and CMS drug negotiations loom.